349 related articles for article (PubMed ID: 15977644)
1. HLA-E protects glioma cells from NKG2D-mediated immune responses in vitro: implications for immune escape in vivo.
Wischhusen J; Friese MA; Mittelbronn M; Meyermann R; Weller M
J Neuropathol Exp Neurol; 2005 Jun; 64(6):523-8. PubMed ID: 15977644
[TBL] [Abstract][Full Text] [Related]
2. HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C.
Braud VM; Allan DS; O'Callaghan CA; Söderström K; D'Andrea A; Ogg GS; Lazetic S; Young NT; Bell JI; Phillips JH; Lanier LL; McMichael AJ
Nature; 1998 Feb; 391(6669):795-9. PubMed ID: 9486650
[TBL] [Abstract][Full Text] [Related]
3. The inhibitory NK cell receptor CD94/NKG2A and the activating receptor CD94/NKG2C bind the top of HLA-E through mostly shared but partly distinct sets of HLA-E residues.
Wada H; Matsumoto N; Maenaka K; Suzuki K; Yamamoto K
Eur J Immunol; 2004 Jan; 34(1):81-90. PubMed ID: 14971033
[TBL] [Abstract][Full Text] [Related]
4. Increased frequency of human leukocyte antigen-E inhibitory receptor CD94/NKG2A-expressing peritoneal natural killer cells in patients with endometriosis.
Galandrini R; Porpora MG; Stoppacciaro A; Micucci F; Capuano C; Tassi I; Di Felice A; Benedetti-Panici P; Santoni A
Fertil Steril; 2008 May; 89(5 Suppl):1490-6. PubMed ID: 17706207
[TBL] [Abstract][Full Text] [Related]
5. NK cell CD94/NKG2A inhibitory receptors are internalized and recycle independently of inhibitory signaling processes.
Borrego F; Kabat J; Sanni TB; Coligan JE
J Immunol; 2002 Dec; 169(11):6102-11. PubMed ID: 12444112
[TBL] [Abstract][Full Text] [Related]
6. HLA-E is expressed on trophoblast and interacts with CD94/NKG2 receptors on decidual NK cells.
King A; Allan DS; Bowen M; Powis SJ; Joseph S; Verma S; Hiby SE; McMichael AJ; Loke YW; Braud VM
Eur J Immunol; 2000 Jun; 30(6):1623-31. PubMed ID: 10898498
[TBL] [Abstract][Full Text] [Related]
7. CD94-NKG2A recognition of human leukocyte antigen (HLA)-E bound to an HLA class I leader sequence.
Petrie EJ; Clements CS; Lin J; Sullivan LC; Johnson D; Huyton T; Heroux A; Hoare HL; Beddoe T; Reid HH; Wilce MC; Brooks AG; Rossjohn J
J Exp Med; 2008 Mar; 205(3):725-35. PubMed ID: 18332182
[TBL] [Abstract][Full Text] [Related]
8. IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.
Malmberg KJ; Levitsky V; Norell H; de Matos CT; Carlsten M; Schedvins K; Rabbani H; Moretta A; Söderström K; Levitskaya J; Kiessling R
J Clin Invest; 2002 Nov; 110(10):1515-23. PubMed ID: 12438449
[TBL] [Abstract][Full Text] [Related]
9. The CD94/NKG2C killer lectin-like receptor constitutes an alternative activation pathway for a subset of CD8+ T cells.
Gumá M; Busch LK; Salazar-Fontana LI; Bellosillo B; Morte C; García P; López-Botet M
Eur J Immunol; 2005 Jul; 35(7):2071-80. PubMed ID: 15940674
[TBL] [Abstract][Full Text] [Related]
10. Kinetics and peptide dependency of the binding of the inhibitory NK receptor CD94/NKG2-A and the activating receptor CD94/NKG2-C to HLA-E.
Valés-Gómez M; Reyburn HT; Erskine RA; López-Botet M; Strominger JL
EMBO J; 1999 Aug; 18(15):4250-60. PubMed ID: 10428963
[TBL] [Abstract][Full Text] [Related]
11. HLA-G recognition by human natural killer cells. Involvement of CD94 both as inhibitory and as activating receptor complex.
Pende D; Sivori S; Accame L; Pareti L; Falco M; Geraghty D; Le Bouteiller P; Moretta L; Moretta A
Eur J Immunol; 1997 Aug; 27(8):1875-80. PubMed ID: 9295021
[TBL] [Abstract][Full Text] [Related]
12. Interactions between NKG2x immunoreceptors and HLA-E ligands display overlapping affinities and thermodynamics.
Kaiser BK; Barahmand-Pour F; Paulsene W; Medley S; Geraghty DE; Strong RK
J Immunol; 2005 Mar; 174(5):2878-84. PubMed ID: 15728498
[TBL] [Abstract][Full Text] [Related]
13. Specific recognition of HLA-E, but not classical, HLA class I molecules by soluble CD94/NKG2A and NK cells.
Brooks AG; Borrego F; Posch PE; Patamawenu A; Scorzelli CJ; Ulbrecht M; Weiss EH; Coligan JE
J Immunol; 1999 Jan; 162(1):305-13. PubMed ID: 9886400
[TBL] [Abstract][Full Text] [Related]
14. Association of CD94/NKG2A, CD94/NKG2C, and its ligand HLA-E polymorphisms with Behcet's disease.
Seo J; Park JS; Nam JH; Bang D; Sohn S; Lee ES; Park KS
Tissue Antigens; 2007 Oct; 70(4):307-13. PubMed ID: 17767552
[TBL] [Abstract][Full Text] [Related]
15. HLA-E is a major ligand for the natural killer inhibitory receptor CD94/NKG2A.
Lee N; Llano M; Carretero M; Ishitani A; Navarro F; López-Botet M; Geraghty DE
Proc Natl Acad Sci U S A; 1998 Apr; 95(9):5199-204. PubMed ID: 9560253
[TBL] [Abstract][Full Text] [Related]
16. Expression of p58.2 or CD94/NKG2A inhibitory receptors in an NK-like cell line, YTINDY, leads to HLA Class I-mediated inhibition of cytotoxicity in the p58.2- but not the CD94/NKG2A-expressing transfectant.
Lin Chua H; Brahmi Z
Cell Immunol; 2002 Sep; 219(1):57-70. PubMed ID: 12473268
[TBL] [Abstract][Full Text] [Related]
17. The natural killer cell-mediated killing of autologous dendritic cells is confined to a cell subset expressing CD94/NKG2A, but lacking inhibitory killer Ig-like receptors.
Della Chiesa M; Vitale M; Carlomagno S; Ferlazzo G; Moretta L; Moretta A
Eur J Immunol; 2003 Jun; 33(6):1657-66. PubMed ID: 12778484
[TBL] [Abstract][Full Text] [Related]
18. Analysis of HLA-E peptide-binding specificity and contact residues in bound peptide required for recognition by CD94/NKG2.
Miller JD; Weber DA; Ibegbu C; Pohl J; Altman JD; Jensen PE
J Immunol; 2003 Aug; 171(3):1369-75. PubMed ID: 12874227
[TBL] [Abstract][Full Text] [Related]
19. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition.
Michaëlsson J; Teixeira de Matos C; Achour A; Lanier LL; Kärre K; Söderström K
J Exp Med; 2002 Dec; 196(11):1403-14. PubMed ID: 12461076
[TBL] [Abstract][Full Text] [Related]
20. HLA-G1 co-expression boosts the HLA class I-mediated NK lysis inhibition.
Riteau B; Menier C; Khalil-Daher I; Martinozzi S; Pla M; Dausset J; Carosella ED; Rouas-Freiss N
Int Immunol; 2001 Feb; 13(2):193-201. PubMed ID: 11157852
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
